NASDAQ:MEDX - Nasdaq - US53656G5633 - ETF - Currency: USD
The company is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year.
Recently, the company announced a massive $15 billion share buyback plan and a 15% dividend increase.